This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ruggeri, B. Articles by Klein-Szanto, A. J. P. Search for Related Content PubMed PubMed Citation Articles by Ruggeri, B. Articles by Klein-Szanto, A. J. P.

Alterations of the p53 Tumor Suppressor Gene during Mouse Skin Tumor Progression¹

Department of Pathology, Institute for Cancer Research, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111 [B. R., J. C., M. D., A. J. P. K.]; Merck, Sharp and Dohme Research Laboratories, West Point, Pennsylvania 19486 [T. G.]; and Department of Carcinogenesis, The University of Texas M. D. Anderson Cancer Center, Smithville, Texas 78957 [A. B., D. T., C. J. C.]

The two-stage murine skin tumorigenesis model is widely used to study the development of squamous cell neoplasias. We have investigated expression of the p53 and retinoblastoma tumor suppressor genes in eight murine skin tumor cell lines of varied histopathology and malignant potential, in seven in vivo-derived clones from these cell lines, and in 39 primary short-term cultures of similarly induced skin tumors at various stages of tumor progression. One squamous cell carcinoma cell line and three more malignant clones derived from it revealed mutations of the p53 protein by immunoprecipitation analyses despite normal-sized p53 transcripts. Sequence analysis identified the nature of the point mutations in these lines, a GC transversion in codon 132. Mouse retinoblastoma transcripts and protein were unaltered in all the cell lines examined. Among short-term cultures of skin tumors, the p53 gene appeared normal in all papillomas and early well-differentiated carcinomas by Southern and immunoprecipitation analyses. In contrast, four of eight tumors from later stages of promotion (50–60 weeks) possessed alterations in p53, including loss of the p53 product, and loss of immunoreactivity with a murine-specific antibody recognizing only wild-type p53 protein. Loss of heterozygosity at the p53 locus was similarly observed in several more malignant tumors from later stages of promotion. In contrast retinoblastoma expression was normal regardless of the stage of promotion or histological grade of the tumor. Direct sequence analyses of exons 5 through 8 of the p53 gene in eight advanced murine skin tumors revealed a 25% incidence of p53 mutations. These point mutations were located in codons 245 and 263. Collectively, these data indicate that alterations in the p53 gene occur in 25 to 50% of murine skin tumors induced by the two-stage tumorigenesis protocol and are later events in murine skin tumor progression. Moreover, these alterations are associated with tumors possessing a more malignant and/or poorly differentiated phenotype.

¹ This work was supported by NIH Grants CA53713, CA44980, CA06927, CA53123, and RR05895, and an appropriation from the Commonwealth of Pennsylvania.

² To whom requests for reprints should be addressed, at Department of Pathology, Fox Chase Cancer Center, 7701 Burholme Avenue, Philadelphia, PA 19111.

Received 6/18/91. Accepted 10/28/91.

This article has been cited by other articles:

				C. D. Knights, Y. Liu, E. Appella, and M. Kulesz-Martin Defective p53 Post-translational Modification Required for Wild Type p53 Inactivation in Malignant Epithelial Cells with mdm2 Gene Amplification J. Biol. Chem., December 26, 2003; 278(52): 52890 - 52900. [Abstract] [Full Text] [PDF]

				H. Mahloogi, A. M. Gonzalez-Guerrico, R. Lopez De Cicco, D. E. Bassi, T. Goodrow, K.-H. Braunewell, and A. J. P. Klein-Szanto Overexpression of the Calcium Sensor Visinin-like Protein-1 Leads to a cAMP-mediated Decrease of in Vivo and in Vitro Growth and Invasiveness of Squamous Cell Carcinoma Cells Cancer Res., August 15, 2003; 63(16): 4997 - 5004. [Abstract] [Full Text] [PDF]

				H. Mahloogi, D. E. Bassi, and A. J.P. Klein-Szanto Malignant conversion of non-tumorigenic murine skin keratinocytes overexpressing PACE4 Carcinogenesis, April 1, 2002; 23(4): 565 - 572. [Abstract] [Full Text] [PDF]

				A. Balmain and C. C.Harris Carcinogenesis in mouse and human cells: parallels and paradoxes Carcinogenesis, March 1, 2000; 21(3): 371 - 377. [Abstract] [Full Text] [PDF]

				P. J. Reddig, N. E. Dreckschmidt, J. Zou, S. E. Bourguignon, T. D. Oberley, and A. K. Verma Transgenic Mice Overexpressing Protein Kinase C{{epsilon}} in Their Epidermis Exhibit Reduced Papilloma Burden but Enhanced Carcinoma Formation after Tumor Promotion Cancer Res., February 1, 2000; 60(3): 595 - 602. [Abstract] [Full Text]

				D. M. Owens, S.-J. C. Wei, and R. C. Smart A multihit, multistage model of chemical carcinogenesis Carcinogenesis, September 1, 1999; 20(9): 1837 - 1844. [Abstract] [Full Text] [PDF]

				M. L. Rodriguez-Puebla, M. LaCava, and C. J. Conti Cyclin D1 Overexpression in Mouse Epidermis Increases Cyclin-dependent Kinase Activity and Cell Proliferation in Vivo but Does Not Affect Skin Tumor Development Cell Growth Differ., July 1, 1999; 10(7): 467 - 472. [Abstract] [Full Text]

				C. Go, P. Li, and X.-J. Wang Blocking Transforming Growth Factor {beta} Signaling in Transgenic Epidermis Accelerates Chemical Carcinogenesis: A Mechanism Associated with Increased Angiogenesis Cancer Res., June 1, 1999; 59(12): 2861 - 2868. [Abstract] [Full Text] [PDF]